Methoxyflurane (MOF) as an agent for dental sedation has been used safely in Australasia for decades. The drug is now licensed for relief of pain associated with trauma and is being used during several medical outpatient procedures in the stead of traditional intravenous agents for sedation in the UK. Our aim was to analyse the safety and feasibility of the introduction of MOF as a drug for dental sedation in the UK community setting and assess its environmental impact. A literature review was conducted for available studies and a research audit of medical histories of patients that received nitrous oxide sedation in the previous year was carried out to assess suitability for MOF administration. The published literature shows MOF to be a safe drug for administration in the dental environment and local patients receiving nitrous oxide sedation are medically suitable for MOF administration. The advantages of considering MOF sedation are its environmental benefit and patient acceptability.

甲氧氟烷 (MOF) 作为牙科镇静剂已在澳大利亚安全使用数十年。该药物现已获得许可用于缓解与创伤相关的疼痛，并在英国的多个医疗门诊手术中使用，以代替传统的静脉注射镇静剂。我们的目的是分析在英国社区环境中引入 MOF 作为牙科镇静药物的安全性和可行性，并评估其环境影响。对现有研究进行了文献综述，并对前一年接受一氧化二氮镇静的患者的病史进行了研究审核，以评估 MOF 给药的适合性。已发表的文献显示 MOF 是一种在牙科环境中给药的安全药物，并且接受笑气镇静的当地患者在医学上适合 MOF 给药。考虑 MOF 镇静的优点是其环境效益和患者可接受性。